RxDoctor Payments DataLook up a doctor →

Anand Bhuptani, MD

Pulmonary Disease · Terre Haute, INNPI 1144200114

Payments from drug & device makers

$50,468in general payments, 2019–2025

Across 664 payments — averaging $76.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$35K
  • Boehringer Ingelheim$5K
  • AstraZeneca$4K
  • Grifols USA, LLC$2K
  • Electromed, Inc.$691
  • Jazz Pharmaceuticals Inc.$572
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$41,16382%
  • Food & beverage$9,25318%
  • Education$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,468 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$298,419
Medicare patients
1,187
Services billed
4,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate40$415,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter489$388,623
HizentraImmun Glob G(Igg)/Pro/Iga 0-5011$80,174
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$67,926
Breo ElliptaFluticasone/Vilanterol118$49,699
Dupixent SyringeDupilumab12$44,609
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$33,603
Spiriva RespimatTiotropium Bromide59$32,110
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$10,670
Albuterol Sulfate HfaAlbuterol Sulfate440$10,510
Advair HfaFluticasone Propion/Salmeterol22$9,550
SymbicortBudesonide/Formoterol Fumarate32$8,500
Combivent RespimatIpratropium/Albuterol Sulfate16$7,942
Fluticasone-VilanterolFluticasone/Vilanterol11$5,543
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$5,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$34,859$471,926677 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$4,987$466,696131 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,748$76,426129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →